Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Probiotics  COVID-19 treatment studies for Probiotics  C19 studies: Probiotics  Probiotics   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Symptom resolution 40% Improvement Relative Risk Resolution of fever 38% Catinean et al. Probiotics for COVID-19 Prophylaxis Is prophylaxis with probiotics beneficial for COVID-19? Retrospective 120 patients in Romania (September 2020 - February 2021) Improved recovery with probiotics (p=0.0082) Catinean et al., Nutrients, doi:10.3390/nu15030488 Favors probiotics Favors control
Ongoing Treatment with a Spore-Based Probiotic Containing Five Strains of Bacillus Improves Outcomes of Mild COVID-19
Catinean et al., Nutrients, doi:10.3390/nu15030488
Catinean et al., Ongoing Treatment with a Spore-Based Probiotic Containing Five Strains of Bacillus Improves Outcomes of Mild.., Nutrients, doi:10.3390/nu15030488
Jan 2023   Source   PDF  
  All Studies   Meta
Retrospective 60 patients in Romania taking probiotics and 60 matched controls, showing faster symptom resolution with the use of probiotics. Spore-based probiotic containing five strains of Bacillus.
The immune effects of probiotics are strain-specific.
symptom resolution, 40.5% lower, HR 0.60, p = 0.008, treatment 60, control 60, inverted to make HR<1 favor treatment.
resolution of fever, 37.5% lower, HR 0.62, p = 0.02, treatment 60, control 60, inverted to make HR<1 favor treatment, fever.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Catinean et al., 17 Jan 2023, retrospective, Romania, peer-reviewed, 4 authors, study period 15 September, 2020 - 15 February, 2021.
Contact: (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperProbioticsAll
Abstract: nutrients Article Ongoing Treatment with a Spore-Based Probiotic Containing Five Strains of Bacillus Improves Outcomes of Mild COVID-19 Adrian Catinean 1 , Anamaria Sida 1, *, Celina Silvestru 1 and Gheorghe G. Balan 2 1 2 * Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania Department of Gastroenterology, Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania Correspondence: Abstract: Spore-based Bacillus probiotic treatment improves intestinal health. The intestinal microbiota influences both the innate and adaptive immune responses. As such, the influence of ongoing spore-based probiotic treatment (five probiotic strains of Bacillus) on the clinical outcomes of mild COVID-19 was evaluated in this retrospective, observational study. Demographics, medical history, probiotic use, and COVID-19 symptom information were collected. The study included 120 patients with a PCR-confirmed SARS-CoV-2 infection and mild COVID-19 symptoms. The probiotic group (n = 60) comprised patients with ongoing probiotic treatment (≥1 month); the control group comprised patients not taking probiotics (n = 60). The primary outcome was time to symptom resolution; secondary outcomes included time to fever resolution and presence of digestive symptoms. The probiotic group had a significantly shorter time to symptom resolution (mean (95% confidence interval) days: control group, 8.48 (6.56, 10.05); probiotic group, 6.63 (5.56; 6.63); p = 0.003) and resolution of fever (control group, 2.67 (1.58, 3.61); probiotic group, 1.48 (1.21, 2.03); p < 0.001). More patients in the probiotic group (n = 53) than in the control group (n = 34) did not have digestive symptoms (p < 0.001). Among adults with mild COVID-19, participants receiving ongoing probiotic treatment had a shorter clinical course, and fewer had digestive symptoms compared with those not taking probiotics. Citation: Catinean, A.; Sida, A.; Keywords: Bacillus; COVID-19; probiotics; SARS-CoV-2; time to symptom resolution; gut microbiota; gut–lung axis; gastrointestinal COVID-19 symptoms; immunomodulation; fever in COVID-19 infection Silvestru, C.; Balan, G.G. Ongoing Treatment with a Spore-Based Probiotic Containing Five Strains of Bacillus Improves Outcomes of Mild COVID-19. Nutrients 2023, 15, 488. nu15030488 Academic Editor: Gang Wang Received: 16 December 2022 Revised: 5 January 2023 Accepted: 12 January 2023 Published: 17 January 2023 Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// 4.0/).
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop